| Median age, y (range) . | 36.56 (16-58) . | ||
|---|---|---|---|
| Sex . | 26 males, 4 females . | ||
| Disease . | n (%) . | Salvage Rx/mobilization . | Conditioning regimen . |
| Multiple myeloma | 11 (36.66) | VCD/RVD/+ Cy-GCSF | Melphalan |
| HD | 6 (9.20) | ICE(05)/ GND(02)/ + GCSF | BEAM |
| DLBCL | 5 (16.66) | RICE(05)/ + GCSF | BEAM |
| PTCL | 4 (13.33) | ICE(04)/+GCSF | BEAM |
| AML | 3 (10) | HiDAC(03)/+ GCSF | Bu-Cy |
| Plasmablastic lymphoma | 1 (3.33) | DA EPOCH + bortezomib/GCSF | BEAM |
| Median age, y (range) . | 36.56 (16-58) . | ||
|---|---|---|---|
| Sex . | 26 males, 4 females . | ||
| Disease . | n (%) . | Salvage Rx/mobilization . | Conditioning regimen . |
| Multiple myeloma | 11 (36.66) | VCD/RVD/+ Cy-GCSF | Melphalan |
| HD | 6 (9.20) | ICE(05)/ GND(02)/ + GCSF | BEAM |
| DLBCL | 5 (16.66) | RICE(05)/ + GCSF | BEAM |
| PTCL | 4 (13.33) | ICE(04)/+GCSF | BEAM |
| AML | 3 (10) | HiDAC(03)/+ GCSF | Bu-Cy |
| Plasmablastic lymphoma | 1 (3.33) | DA EPOCH + bortezomib/GCSF | BEAM |